ATG16L1 and colorectal carcinoma: This, along with the improved immunotherapy response (Fig. 1a) and elevated T/NK cell-associated gene signatures (Fig. 1f) in ATG16L1-low patient subsets prompted us to evaluate the impact of cellular immunity on CRC growth in vivo.